<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Leucocytes from <z:mpath ids='MPATH_458'>normal</z:mpath> individuals and from patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) in remission receiving active immunotherapy with allogeneic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-I) were cultured for 6 days with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-I blasts, Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) or lymphoblastoid cells (LCL) </plain></SENT>
<SENT sid="1" pm="."><plain>The leucocytes were then tested for cell-mediated cytotoxicity (CMC) against <z:chebi fb="0" ids="50076">51Cr</z:chebi>-labelled <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-I, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> or LCL target cells </plain></SENT>
<SENT sid="2" pm="."><plain>There was no substantial difference in the CMC of leucocytes from patients and <z:mpath ids='MPATH_458'>normals</z:mpath> cultured without stimulation, and tested against <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-I, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> or LCL targets </plain></SENT>
<SENT sid="3" pm="."><plain>Patient's leucocytes stimulated in vitro with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-I had a greater frequency of positive CMC responses against <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-I, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and LCL than <z:mpath ids='MPATH_458'>normal</z:mpath> individuals </plain></SENT>
<SENT sid="4" pm="."><plain>The results suggest that co-cultivation of leucocytes with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-I blasts reactivates memory cytotoxic leucocytes in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients receiving immunotherapy and that this test may be useful in measuring the effectiveness of immunotherapy </plain></SENT>
</text></document>